Photocure ASA

Board/Management Information • Jul 1, 2020

Photocure appoints Susanne Strauss as Vice President and General Manager of Europe

Photocure appoints Susanne Strauss as Vice President and General Manager of Europe

Oslo, Norway, 1 July 2020: Photocure ASA (OSE:PHO), today announced the

appointment of Susanne Strauss as Vice President and General Manager of Europe,

effective 1 July 2020.

[image]

"I am pleased to welcome Susanne Strauss to the Photocure team and I am

confident that Susanne's background and experience will lend itself to the

success launch of our European-wide organization this fall. Susanne will report

directly to me in her role and will be a member of Photocure's leadership team.

In addition, as part of building the larger European organization, we will

integrate our current Nordic operation led by Kristin Nyberg under Susanne's

leadership," says Dan Schneider, President and Chief Executive Officer of

Photocure.

Ms. Strauss brings over 20 years of international leadership experience in

medical devices, life sciences and pharma, living and working across Europe and

Asia with occasional remits in the U.S. Most recently Ms. Strauss held the

position of General Manager of Asia Pacific for legacy BTG at Boston Scientific

based in Hong Kong after leading BTG's Interventional Pulmonology Business as VP

Commercial and expanding BTG's Interventional Oncology Business into Europe.

Before that she worked in leadership positions for companies such as Convatec,

Janssen-Cilag and Baxter. She holds a PhD in Technical Chemistry and an MBA from

SDA Bocconi.

The appointment follows the agreement to regain the Hexvix[®] sales, marketing

and distribution rights in Europe and other markets currently controlled by

Ipsen Pharma SAS on 1 October 2020.

"To execute on this opportunity and its global strategy, Photocure is

establishing its commercial operations in Europe, with key leads already hired

both at country level and in the global functions to support the European

organization," Schneider adds. Ms. Strauss and these key leaders will be part of

the ongoing comprehensive transition activities in collaboration with Ipsen

teams. Ms. Strauss will establish a European Headquarters, hire the European

commercial team and oversee the integration with other functions to form a

complete European organization. She will work on the development of new growth

strategies and the execution of tactics in key markets throughout Europe.

"The transition activities are on track and Photocure is in the process of

establishing a distribution and third-party logistics network. We are fully

confident that we will be operationally and commercially ready for a smooth

handover on October 1. The ongoing transition activities are being facilitated

by our deep knowledge of the disease state and our product. We intend to

leverage our expertise by applying the commercial success and strong growth in

the Nordic and the U.S. markets to the European region," Schneider concludes.

Notes to editors

About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)

Hexvix[®]/Cysview[®] is a drug that is selectively taken up by tumor cells in

the bladder making them glow bright pink during Blue Light Cystoscopy (BLC[TM]).

BLCT with Hexvix[®] /Cysview[®] improves the detection of tumors and leads to

more complete resection, fewer residual tumors and better management decisions.

Cysview[®] is the tradename in the U.S. and Canada, Hexvix[®] is the tradename

in all other markets.

About Bladder Cancer

Bladder cancer ranks as the sixth most common cancer worldwide with 1 650 000

prevalent cases (5-year prevalence rate), 550 000 new cases and almost 200 000

deaths annually in 2018.[1]Approx. 75% of all bladder cancer cases occur in

men.[1] It has a high recurrence rate with an average of 61% in year one and 78%

over five years.[2] Bladder cancer has the highest lifetime treatment costs per

patient of all cancers.[3]

Bladder cancer is a costly, potentially progressive disease for which patients

have to undergo multiple cystoscopies due to the high risk of recurrence. There

is an urgent need to improve both the diagnosis and the management of bladder

cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer

(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of

invasion in the bladder wall. NMIBC remains in the inner layer of cells lining

the bladder. These cancers are the most common (75%) of all BC cases and include

the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has

grown into deeper layers of the bladder wall. These cancers, including subtypes

T2, T3 and T4, are more likely to spread and are harder to treat.[4]

[1] Globocan. Incidence/mortality by

population. Available at: http://globocan.iarc.fr/Pages/bar_pop_sel.aspx

[2] Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657

[3] Sievert KD et al. World J Urol 2009;27:295-300

[4] Bladder Cancer. American Cancer

Society. https://www.cancer.org/cancer/bladder-cancer.html

For further information, please contact:

Photocure

Dan Schneider

President and CEO

Tel: +1-609 759-6515

Email: ds@photocure.com

Erik Dahl

CFO

Tel: +47 45055000

Email: ed@photocure.com

Media and IR enquiries:

Geir Bjørlo

Corporate Communications (Norway)

Tel: +47 91540000

Email: geir.bjorlo@corpcom.no

About Photocure

Photocure: The Bladder Cancer Company delivers transformative solutions to

improve the lives of bladder cancer patients. Our unique technology, making

cancer cells glow bright pink, has led to better health outcomes for patients

worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo

Stock Exchange (OSE: PHO). For more information, please visit us at

www.photocure.com, www.hexvix.com, www.cysview.com